Pfizer ( will continue to use the Entelos® Cardiovascular PhysioLab® platform for cardiovascular research. The product was originally built by Entelos ( in collaboration with Pfizer. “The pharmaceutical and medical communities recognize the importance of treating complex conditions much earlier in the disease process,” says James Karis, president and CEO of Entelos. “We expect to use our new cardiovascular platform to conduct research that goes much deeper into the biology of heart disease to help identify novel approaches and treatments.”

Next articleUMMZ Periodical Cicada Page